<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04919239</url>
  </required_header>
  <id_info>
    <org_study_id>RUTIP2-2019-01</org_study_id>
    <nct_id>NCT04919239</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Investigate Therapeutic Vaccine (RUTI) Against Tuberculosis (TB)</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled, Phase IIb Clinical Trial to Investigate the Efficacy of RUTI® Therapeutic Vaccination as Adjuvant of Tuberculosis Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Archivel Farma S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Archivel Farma S.L.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized, double-blind, multicentre, placebo-controlled clinical phase IIb&#xD;
      trial to evaluate efficacy of RUTI® vaccine in DS- (Drug-Sensitive) and MDR-TB&#xD;
      (Multidrug-resistant) patients favourably responding to standard MDR-TB treatment. Time point&#xD;
      of vaccination starts upon completion of 1 week of standard DS-TB treatment (cohort A), and&#xD;
      another cohort of patients will be vaccinated upon completion of 1 month of standard MDR-TB&#xD;
      treatment (cohort B). All the patients will be followed up to the end of the treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with Sputum Culture Negative</measure>
    <time_frame>Up to Week 2 for Cohort A and Month 1.5 for Cohort B</time_frame>
    <description>Difference between intervention and control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with Sputum Culture Negative</measure>
    <time_frame>Up to Week 8 for Cohort A and Month 6 for Cohort B</time_frame>
    <description>Difference between intervention and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with reduction of bacillary load</measure>
    <time_frame>Up to Week 2 and 8 (Cohort A); and Months 1.5 and 6 (Cohort B)</time_frame>
    <description>Difference between intervention and control group based upon Time to detection (TTD) signal in MGIT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement of clinical signs and symptoms</measure>
    <time_frame>Up to Week 2 and 8 (Cohort A); and Months 1.5 and 6 (Cohort B)</time_frame>
    <description>Difference between intervention and control group based upon Bandin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical safety parameters related to vaccination</measure>
    <time_frame>Through study completion, an average of 2 year</time_frame>
    <description>Serious adverse events (SAEs) by CTCAE v4.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Local tolerability</measure>
    <time_frame>Up to Week 8</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 in terms of site of injection for redness, pain, swelling, induration and functional limitation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>RUTI® arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A dose of 25 μg of of RUTI vaccine will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be given at week 1 (Cohort A-DS TB Patients) or month 1 (Cohort B-MDR TB Patients) after starting standard TB treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUTI®</intervention_name>
    <description>Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.</description>
    <arm_group_label>RUTI® arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid muscle.</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with pulmonary DS- or MDR-TB, and managed with standard-care TB drugs&#xD;
             accordingly;&#xD;
&#xD;
          2. Attending a TB unit / hospital routinely diagnosed with pulmonary DS- or MDR-TB with&#xD;
             clinical status ≥ 6 with Bandim TB score combined with chest radiography; and&#xD;
             microbiological criteria (MGIT sputum culture), by using rapid genetic testing, gene&#xD;
             Xpert;&#xD;
&#xD;
          3. Patients who have not received any anti-tubercular treatment in last 6 months&#xD;
&#xD;
          4. Females and males aged ≥ 18;&#xD;
&#xD;
               -  females of non-childbearing potential: at least 2 years post- menopausal or&#xD;
                  surgically sterile (e.g. tubal ligation);&#xD;
&#xD;
               -  females of childbearing potential (including females less than 2 years&#xD;
                  postmenopausal) must have a negative pregnancy test at enrolment and must agree&#xD;
                  to use highly effective methods of birth control (i.e. diaphragm plus spermicide&#xD;
                  or male condom plus spermicide, oral contraceptive in combination with a second&#xD;
                  method, contraceptive implant, injectable contraceptive, indwelling intrauterine&#xD;
                  device, sexual abstinence, or a vasectomized partner) while participating in the&#xD;
                  study;&#xD;
&#xD;
               -  males must agree to use a double barrier method of contraception (condom plus&#xD;
                  spermicide or diaphragm plus spermicide) while participating in the study; or the&#xD;
                  male patient or his female partner must be surgically sterile (e.g. vasectomy,&#xD;
                  tubal ligation) or the female partner must be post-menopausal;&#xD;
&#xD;
          5. The patient must provide written informed consent;&#xD;
&#xD;
          6. The patient must be willing and able to attend all study visits and comply with all&#xD;
             study procedures.&#xD;
&#xD;
        Inclusion criteria for vaccination&#xD;
&#xD;
        1. Having successfully completed 1 week or 1 month (depending on the cohort) of DS or&#xD;
        MDR-TB treatment, respectively, fully supervised; and with beneficial initial response to&#xD;
        therapy, evidenced by clinical response.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inability to provide written informed consent;&#xD;
&#xD;
          2. Women reported, or detected, or willing to be pregnant during the trial period;&#xD;
&#xD;
          3. Severity of illness precluding full evaluation: expected early death, evidenced by&#xD;
             respiratory failure, low blood pressure, WHO performance score 3-4&#xD;
&#xD;
          4. Patients with extra-pulmonary tuberculosis&#xD;
&#xD;
          5. Major co-morbid conditions precluding full evaluation, i.e., HIV positive, chronic&#xD;
             renal failure, chronic liver failure, Malignancy, patients taking any&#xD;
             immunosuppressant drug, active lung cancer, acute coronary syndrome, heart failure&#xD;
             exceeding NYHA class 2;&#xD;
&#xD;
          6. Presence of secondary immunodeficiency states: Organ transplantation, diabetes&#xD;
             mellitus&#xD;
&#xD;
          7. Any of the following laboratory parameters:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt; 3 x upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Total bilirubin &gt; 2 x ULN&#xD;
&#xD;
               -  Neutrophil count ≤ 500 neutrophils / mm3&#xD;
&#xD;
               -  Platelet count &lt; 50,000 cells / mm3&#xD;
&#xD;
          8. Cytotoxic chemotherapy or radiation therapy within the previous 3 months;&#xD;
&#xD;
          9. Blood transfusion in the last three weeks prior to the trial; 10.Patients with history&#xD;
             of alcohol or drug abuse&#xD;
&#xD;
        11. Documented allergy to TB vaccines, notably, to the RUTI® vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randeep Guleria, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>All India Institute of Medical Sciences, New Delhi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dipendra K Mitra, Prof</last_name>
    <phone>01126588500</phone>
    <email>salilmitra2@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>All India Institute of Medical Sciences</name>
      <address>
        <city>New Delhi</city>
        <zip>11002</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Dipendra K Mitra, Prof.</last_name>
      <email>salilmitra2@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agartala Government Medical College</name>
      <address>
        <city>Tripura</city>
        <zip>799006</zip>
        <country>India</country>
      </address>
    </facility>
    <contact>
      <last_name>Tapan Majumdar, Dr</last_name>
      <email>drtapan1960@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 31, 2021</study_first_submitted>
  <study_first_submitted_qc>June 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2021</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

